We would like to thank members for their support which has seen the first print run of the PCF5 sell out. In preparing for the second print run, we have identified a few essential changes that unfortunately inevitably occur with the production of such a comprehensive resource and we have made the following corrections to the text. We recommend that you amend your first print run copy accordingly. All necessary changes, where applicable, have been made on the website and in PCF5+ 2015 pdf. Note the website always contains the most up to date content.

Erratum

**Chapter 14: Guidance about prescribing in palliative care**
Page 658 (Box F)
A typesetting error has meant the following transdermal patches are incorrectly listed in the Left hand column (Need to remove before MRI) and should be listed in the Right hand column (No need to remove before MRI):
Estraderm TTS, Estradot, Evorel, Evorel Conti, Evorel Sequi, Fem Seven, FemSeven Conti.

**Chapter 29: Oral nutritional supplements**
Page 803 (Box A; End of life section)
The following missing text (in blue) has been re-inserted:
‘Because cachexia is considered ‘refractory’ in patients with a limited prognosis, i.e. <3 months, the focus of care is on providing symptom relief, addressing patient and family eating-related distress, and the use of appetite stimulants when appropriate.¹
Small amounts of food can be offered as desired by the patient to alleviate hunger, and for pleasure and social purposes.²²b

Minor changes

**Prelims: Summary of main changes**
Page xii
Tapentadol has been added to the list of new monographs

**Abbreviations**
Page xxvii (Table 1)
The word ‘stat’ (Latin abbreviation) has been added to empty cell in the bottom row of the right hand column

**Antimuscarinics**
Page 9 (Box C)
Reference numbers 25 through to 30, have been renumbered as 26 through to 31.

**Stimulant laxatives**
Page 49–51
Reference numbers 6, 7, 8 and 9 (Sykes N 1991; Sykes N 1991; Agra Y et al. 1998 and Ramesh P et al. 1998) have been removed resulting in subsequent renumbering in the text.
www.palliativedrugs.com update

PCF5 reprint changes

**Anticoagulants and LMWH**
Page 86 and page 90
Corrected spelling of pentasaccharide

**Haemostatics**
Page and 101 (Haematuria)
Cross reference to NSAIDs monograph corrected to Table 4, p.311.

**Benzodiazepines**
Page 148 (Pharmacology)
The word ‘a’ has been corrected to an alpha symbol in the following sentence:
The α subunit of the GABA_A receptor, of which there are six subtypes, is the predominant determinant of benzodiazepine affinity and function (Table 1).

**Antidepressants**
Page 191 (Figure 1)
corrected spelling of trazodone.

**Paracetamol**
Page 300 (Pharmacology)
The dosing frequency abbreviation in the last sentence before figure 1 has been changed from q.i.d. (USA format) to q.d.s.

**Codeine**
Page 348 (Pharmacology)
Cross reference to Chapter 25, Table 1 corrected to Chapter 25, Table 8, p.775.

**Fentanyl**
Page 408 (CSCI)
The dosing frequency abbreviation in the second bullet point has been changed from q1 to the correct abbreviation of q1h.

**Methadone**
Page 436 (Table 1)
corrected spelling of tobacco.

**Oropharyngeal candidosis**
Page 466 (Drug interactions)
The drug glyburide (USA name) has been changed to glibenclamide (UK name) and reordered alphabetically.

**Urinary tract infections**
Page 473 (Uncomplicated UTIs)
corrected spelling of trometamol in the last sentence.

There have also been other minor formatting and grammatical/spelling corrections which do not affect clinical use. We apologise for these changes and for any inconvenience. We endeavour to ensure accuracy as far as is humanly possible and we are always grateful for your feedback (hq@palliativedrugs.com).